The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The life-threatening cytokine-release syndrome suffered by six volunteers in a Phase I clinical trial following administration of the CD28 superagonist antibody TGN1412 (developed by TeGenero) in March 2006 was completely unpredicted by the preclinical studies. Here, Thomas Hünig, main founder of TeGenero, describes the recent investigations into what went wrong and discusses the lessons learnt for future clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes
Stefanová, I., Dorfman, J. R., & Germain, R. N. (2002) · Nature · doi:10.1038/nature01146 · Cited by 389
ABRAMOWICZ, D., SCHANDENE, L., GOLDMAN, M., CRUSIAUX, A., VEREERSTRAETEN, P., PAUW, L. D., WYBRAN, J., KINNAERT, P., DUPONT, E., & TOUSSAINT, C. (1989) · Transplantation · doi:10.1097/00007890-198904000-00008 · Cited by 352
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
Lin, C., & Hünig, T. (2003) · European Journal of Immunology · doi:10.1002/eji.200323570 · Cited by 184
Self-citationTacke, M., Hanke, G., Hanke, T., & Hünig, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270136 · Cited by 163
Self-citationRömer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Self-citationRapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K. M., Gold, R., & Hünig, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004643 · Cited by 79
Self-citationHanke, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69651-7 · Cited by 65
Cited by
Items 101–194 of 194
Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice
Lee, W. W. L., Teo, T., Lum, F., Andiappan, A. K., Amrun, S. N., Rénia, L., Rötzschke, O., & Ng, L. F. P. (2016) · Scientific Reports · doi:10.1038/srep37603 · Cited by 17
Chen, L., Qian, W., Pan, F., Li, D., Yu, W., Li, T., Yang, Y., Xu, Q., Ding, J., Dai, R., et al. (2023) · Immunotherapy · doi:10.2217/imt-2023-0256 · Cited by 17
Azcutia, V., Bassil, R., Herter, J. M., Engelbertsen, D., Newton, G. A., Autio, A. K., Mayadas, T. N., Lichtman, A. H., Khoury, S. J., Parkos, C. A., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1215-546rr · Cited by 15
Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?
Christen, U., & Hintermann, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898615 · Cited by 19
“Here, we want to come back to the aforementioned failed phase I trial on Treg activation with the CD28 superagonist teralizumab (TGN1412) by TeGenero (74, 75).”
BackgroundEthical considerations and challenges in first-in-human research
Koonrungsesomboon, N., Laothavorn, J., & Karbwang, J. (2016) · Translational research · doi:10.1016/j.trsl.2016.05.006 · Cited by 22
Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
Zhou, S., Wei, J., Su, S., Chen, F., Qiu, Y., & Liu, B. (2017) · Journal of Cancer · doi:10.7150/jca.19501 · Cited by 16
“However, the further use of antibodies against CD28 has been discouraged as a result of a series of acute and serious adverse events in a phase I clinical trial where super agonist anti-CD28 mAb was tested systemically [46].”
BackgroundHumanized mouse as a tool to predict immunotoxicity of human biologics
Yong, K. S. M., Her, Z., Tan, S. Y., Tan, W. W. S., Liu, M., Lai, F., Heng, S. M., Fan, Y., Chang, K. T. E., Wang, C.-I., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553362 · Cited by 13
Human and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands
Yi, L., Zhao, Y., Wang, X., Dai, M., Hellström, K. E., Hellström, I., & Zhang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086337 · Cited by 17
“by engaging CD137 and CD28, including a systemic inflammatory response involving CD4 T cells and a ‘‘cytokine storm’’ [22].”
BackgroundInflammation, obesity, and the promise of immunotherapy for metabolic disease
O’Rourke, R. W. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.07.010 · Cited by 15
“010 primates, within minutes of administration all subjects experienced a “cytokine storm,” a hyperactivation of the immune system, went into multisystem organ failure, and required months of treatment in the intensive care unit [2].”
Human-like Response of Pig T Cells to Superagonistic Anti-CD28 Monoclonal Antibodies
Uehlein, S., Ding, X., Flößer, J., Schmidt, S., Steitz, J., Bille, M., Schnitter, F., Baltes, S., Saalmüller, A., Gerner, W., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100174 · Cited by 15
Levin, L. A., Miller, J. W., Zack, D. J., Friedlander, M., & Smith, L. E. H. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.02.017 · Cited by 14
El-Taibany, A. A., Heydarian, P., Porada, D. A., Seeds, M. C., & Atala, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1595276 · Cited by 12
CD 28 costimulation: W alking the immunological tightrope
Sansom, D. M., & Walker, L. S. K. (2013) · European Journal of Immunology · doi:10.1002/eji.201243211 · Cited by 10
Williams, M. J., Mullane, K., & Curtis, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00005-7 · Cited by 13
Salih, H. R., & Jung, G. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910874 · Cited by 9
“This is exemplified by the deleterious “TeGenero incident” involving a “superagonistic” CD28 antibody that induced life-threatening CRS in six healthy volunteers (Hunig, 2012).”
BackgroundImmunity strikes: heart failure as a systemic disease
Hofmann, U., & Frantz, S. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht405 · Cited by 13
Singh, S., Kachhawaha, K., & Singh, S. K. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116303 · Cited by 13
Charles, J., Vrionis, A., Mansur, A., Mathias, T. J., Shaikh, J., Ciner, A., Jiang, Y., & Nezami, N. (2023) · Cancers · doi:10.3390/cancers15092624 · Cited by 8
“Immunotherapy surrounding CD28 to date has been generally unsuccessful, as early CD28 agonist trials were commonly abandoned in phase I due to severe toxicities and side effect profiles [175,176].”
BackgroundMyers, L. P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8549-4_2 · Cited by 8
Elsayed, A., Pellegrino, C. E., Plüss, L., Peissert, F., Benz, R., Ulrich, F., Thorhallsdottir, G., Plaza, S. D., Villa, A., Mock, J., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2220839 · Cited by 10
Humanized Mouse Models for Type 1 Diabetes Including Pancreatic Islet Transplantation
Rahmig, S., Bornstein, S. R., Chavakis, T., Jaeckel, E., & Waskow, C. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1390446 · Cited by 8
Aschmoneit, N., Kühl, L., Seifert, O., & Kontermann, R. E. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003616 · Cited by 7
Biologics in pregnancy – for the obstetrician
Soh, M. C., & Mackillop, L. H. (2016) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12250 · Cited by 7
Langenhorst, D., Tabares, P., Gulde, T., Becklund, B. R., Berr, S., Surh, C. D., Beyersdorf, N., & Hünig, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01985 · Cited by 9
“Expert Opin Biol Ther (2006) 6(12):1323–31.”
BackgroundSelf-citationHaack, S., Baiker, S., Schlegel, J. A., Sauer, M., Sparwasser, T. D., Langenhorst, D., & Beyersdorf, N. (2020) · European Journal of Immunology · doi:10.1002/eji.202048803 · Cited by 5
Joint representation of molecular networks from multiple species improves gene classification
Mancuso, C. A., Johnson, K. A., Liu, R., & Krishnan, A. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011773 · Cited by 6
Critical Aspects of Integrated Nonclinical Drug Development
Koch, E., & Plassmann, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00002-5 · Cited by 6
Kalden, J. R. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0122-2 · Cited by 5
Chen, M., Liu, X.-Y., Peng, N., Zhang, T.-M., Mou, J.-L., He, H.-Z., Wang, Y., Xu, Y.-X., Xing, H., Tang, K., et al. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00423-0 · Cited by 5
“Even though CD28 signal indeed enhanced fusion protein antibodies in pre-clinical research, we cannot ignore the lessons from the CD28 super agonist TGN1412 trial, in which six volunteers suffered lifethreatening cytokine-release syndrome (CRS) [19, 20].”
BackgroundTherapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00032-1 · Cited by 8
Safety Assessment of Pharmaceuticals
Kenna, J. G., & Ram, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813697-3.00020-2 · Cited by 6
Genomic profiling of T cell activation reveals dependency of memory T cells on CD28 costimulationPreprint
Glinos, D. A., Soskic, B., Jostins, L., Sansom, D. M., & Trynka, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/421099 · Cited by 5
“In addition, severe adverse reactions were observed during trials of a CD28 agonistic antibody TGN1412, which triggered a cytokine storm from effector memory T cells (Eastwood et al., 2010; Hünig, 2012).”
BackgroundSaadany, T. E., Seitz, C., Bräm, C., & Szucs, T. D. (2024) · Journal of Law and the Biosciences · doi:10.1093/jlb/lsae012 · Cited by 4
Sharma, V. K., & Kelley, R. F. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-2543-8_10 · Cited by 4
Therapeutic Antibodies and Immunologic Conjugates
Dobrenkov, K., & Cheung, N. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00030-x · Cited by 5
IMMUNE MODULATION OF CANCER: MECHANISMS AND RESISTANCE
Lisi, L., Cari, L., Sorrentino, R., Mini, E., Fimognari, C., & Nocentini, G. (2021) · doi:10.36118/pharmadvances.2021.07 · Cited by 4
Baum, C. E., Mierzejewska, B., Schroder, P. M., Khattar, M., & Stepkowski, S. M. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.849573 · Cited by 4
Blümel, J., Korte, S., Schenck, E., & Weinbauer, G. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00035-4 · Cited by 3
Roelcke, V. (2022) · Science in Context · doi:10.1017/s0269889723000170 · Cited by 5
“…he explained that the three preclinical “ test systems ” each addressed different aspects of the mechanisms triggered by TGN1412, which only if seen together may yield a comprehensive view of the relevant combined dynamics initiated by the compound (Pallarey & Hünig 2010, 510; Hünig 2012, 318).”
BackgroundInfluentialInterplay between CD28 and PD-1 in T cell immunotherapy
Jafri, Z., Zhang, J., O’Meara, C. H., Joshua, A. M., Parish, C. R., & Khachigian, L. M. (2024) · Vascular Pharmacology · doi:10.1016/j.vph.2024.107461 · Cited by 5
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology
Kwon, H., & Lee, C. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.005 · Cited by 2
[Progress in monoclonal antibody-based immunotherapy for cancer treatment].
Guo, Y. (2015) · PubMed · Cited by 2
Ethical and practical issues in phase 1 trials in healthy volunteers
Senn, S. J. (2014) · doi:10.1002/9781118763070.ch4 · Cited by 2
Chen, W., Xie, A., Wu, J., & Chan, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00007-5 · Cited by 1
Constructing co-stimulation to boost TCR therapy
Höbart, J., & Ruland, J. (2024) · Nature Cancer · doi:10.1038/s43018-024-00746-9 · Cited by 1
Budhavaram, N. K., Duffy, K. H., Abouzeid, A. H., Bharadwaj, R., Shrestha, N., Echeverri, E. S., Mitchener, C., & Subramony, J. A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115893 · Cited by 2
Fraser, S., & Osgood, S. M. (2017) · Bioanalysis · doi:10.4155/bio-2017-0155 · Cited by 1
Swords to Ploughshares and Back: The Continuing Threat of Immunomodulatory Research and Development
Cornish, J. P., & Johnson, R. F. (2019) · Springer eBooks · doi:10.1007/978-3-030-03053-7_10 · Cited by 1
Wallstabe, J., Bussemer, L., Groeber-Becker, F., Freund, L., Alb, M., Dragan, M., Waaga-Gasser, A. M., Jakubietz, R., Kneitz, H., Rosenwald, A., et al. (2020) · ALTEX · doi:10.14573/altex.1907181 · Cited by 1
“, 2016), therefore translation of results to humans may be complicated and can potentially delay drug development and even affect patient safety (Perel et al., 2007; Cook et al., 2012; Johnson et al., 2006; Hunig, 2012).”
BackgroundRodgers, J. B., & Ritskes-Hoitinga, M. J. (2021) · Laboratory animal science and medicine · doi:10.1007/978-3-030-66147-2_10 · Cited by 1
Toda, T., & Nakamura, K. (2014) · Wiley eBooks · doi:10.1002/9783527676965.ch7 · Cited by 1
CD28 Costimulation and Regulatory T Cells
Soskic, B., & Sansom, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.30078-5 · Cited by 2
CD28 Costimulation and Regulatory T Cells
Soskic, B., & Sansom, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30078-5
Promises and Challenges with Immunomodulatory Biologics
Ponce, R. A. (2014) · Wiley eBooks · doi:10.1002/9783527676965.ch8
Participation of Hypertension Patients in Early‐Phase Clinical Trials
Borron, P., Cohen, O. J., Hoofwijk, T. J., & Turner, J. R. (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12296
Redirected T cell activity by high affinity TCR-ANTI-CD3 bispecific candidate therapeutics
Adams, K. J. (2013) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
Bluemel, J. (2012)
Drug Development Strategies for Therapeutic Biologics: Industry Perspectives
Yuraszeck, T. M., & Gibbs, M. A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse559
Impact of Obesity and Aging on the Tumor Immuno-Environment
Mirsoian, A., Sckisel, G. D., Zamora, A. E., & Murphy, W. J. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_9
Afterword: returning to philosophical foundations in research ethics
Eyal, N. (2016) · Journal of Medical Ethics · doi:10.1136/medethics-2016-103429
Long, C. M. (2016) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6108
“This assay was initially developed by Gerberick, et al in 2004 and has been refined since then (97).”
MethodImmune Therapies in Phase 1 Trials
Postel-Vinay, S. C., & Soria, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_32
Carratalá, J. V., Cano‐Garrido, O., Sánchez, J. M., Membrado, C., Pérez, E., Conchillo‐Solé, O., Daura, X., Sánchez‐Chardi, A., Villaverde, A., Arı́s, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/510636
“The precise analysis of recombinant proteins is important 400 due to safety concerns, and specific regulatory guidelines were redesigned for protein‐ 401 based pharmaceuticals after the TGN1412 clinical trial (66,67).”
BackgroundWang, H., Yang, Z., & Shi, R. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch4
Predicting Gene Expression Between Species with Neural NetworksPreprint
Eastman, P. K., & Pande, V. S. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1907.03041
“For example, a drug that appears safe in rodents may turn out to be highly toxic in humans [2], and vice versa.”
BackgroundOrigins and Evolution of Drug Regulation
Williams, K. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-17148-3_2
Cytokine release syndrome: a primer for generalists
Soares, T., & Fok, H. (2019) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000044
Toxicology and Nonclinical Safety Assessment in Pharmaceutical Discovery and Development
Reynolds, V. L., Abernathy, M. M., Baracani, R., Bhalli, J. A., Morford, L. L., Steeves, M. A., & Wang, W. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc291
de Visser, S. J., & Truebel, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00018-0
External stimuli-responsive nanomedicine for cancer immunotherapy
Niu, L., Jang, E., Chin, A. L., & Tong, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00026-9 · Cited by 1
Die Rolle des ko-stimulatorischen Moleküls CD28 in verschiedenen Phasen der EAE
Hufschmidt, J. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6671
Faculty Opinions recommendation of CD28 costimulation: from mechanism to therapy.
Tuosto, L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726363559.793546230
McGeachy, M. J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732850338.793546604
Papenfuss, T. L., & Peachee, V. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64230-7
Chen, L., Qian, W., Pan, F., Li, D., Yu, W., Li, T., Yang, Y., Xu, Q., Ding, J., Dai, R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2474795/v1
Leach, M. W., & Hammerman, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00024-5
Research and discovery: Essential partners but just a start
Miller, S. M., Moos, W. H., Munk, B. H., Munk, S. A., Hart, C. P., & Spellmeyer, D. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00011-0
Aktivierung von Immunzellrezeptoren statt Checkpointblockade
Bald, T., & Glodde, N. (2023) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-023-0035-6
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · Journal of Visualized Experiments · doi:10.3791/65087 · Cited by 1
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · doi:10.3791/65087-v
Intratumoral Delivery of Novel Therapies
Adnan, A., & Sheth, R. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-51192-0_115-1
Koch, E., & Plassmann, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00021-9
Loberg, L. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00041-3 · Cited by 1
Papenfuss, T. L., & Peachee, V. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00038-3
CD28 : nouvelles données sur un récepteur majeur de la costimulation lymphocytaire T
Morin, S. O. (2017) · theses.fr (ABES) · doi:10.70675/cb01635fz2f63z43e2zad0cz210485c4c5cf
Local Anti-CTLA4 Cancer Immunotherapy From Bench to Bedside
Tselikas, L. (2021) · theses.fr (ABES) · doi:10.70675/7e1fa4d8z5408z419bz9394z19ae17697026
Analyse protéomique et interactomique de l'activation des lymphocytes T humains primaires
Nicolas, P. (2021) · theses.fr (ABES) · doi:10.70675/defcbd86z76d7z43bfz9103zb8a743a479f5
Li, Q., Liu, Y., Wang, Y., & Li, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1823374
“Similarly, in non-human primates, CD28 expression on CD4 + effector memory T cells differs from that in humans, meaning cynomolgus macaques cannot reliably predict safety issues, as seen with the CD28 superagonist TGN1412 (57, 58).”
Realizing the potential of agonistic antibody immunotherapy
Cragg, M. S., Yu, X., Paluch, C., & Davis, S. J. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01442-2 · Cited by 2
“It has been debated whether these effects could have been foreseen 151,152 , but the reasons why preclinical testing of TGN1412 failed to anticipate CRS in humans are now clear.”
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44367-1.00006-4
Almeida-Nunes, D. L., Mendes‐Frias, A., Nunes, M., Ferreira, V., Lobo, C., Monteiro, P., Abreu, M. H., Bartosch, C., Nóbrega, C., Dinis‐Oliveira, R. J., et al. (2026) · Cancers · doi:10.3390/cancers18162612
“Since systemic CD28 agonism is associated with cytokine-release toxicity, alternative co-stimulatory strategies such as tumor-targeted [62] or CD27 agonists [63] or APC-activating agents (e.g., CD40L agonists) may offer safer means of reproducing the co-stimulatory effects observed ex-vivo [64].”
Immunotherapy of malignant melanoma using T cell–activating microbeads
Hassan, N. T., Löffler, J., dos Santos, A. S., Wohlfarth, J., Wußmann, M., Schellhammer, L., Berg, J. V., Groeber-Becker, F., Kerkau, T., Schilling, B., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag191
Bioengineered In vitro bone marrow models of acute myeloid leukemia for novel drug discovery
Balanza, C. R., Clarke, L., Dalby, M. J., & Donnelly, H. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2723800
Intratumoral Delivery of Novel Therapies
Adnan, A., & Sheth, R. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-49762-9_115
Metadata
- Authors
- Hünig, T.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Hünig, Thomas
- Venue
- Nature Reviews Immunology
- Published
- 2012-04-10
- Volume
- 12
- Issue
- 5
- Pages
- 317-318
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2080341180
- Cited by
- 194
- References
- 14
- Citations by year
- 2026: 8 · 2025: 2 · 2024: 14 · 2023: 11 · 2022: 3 · 2021: 16 · 2020: 10 · 2019: 17 · 2018: 16 · 2017: 19 · 2016: 20 · 2015: 21 · 2014: 15 · 2013: 16 · 2012: 6
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGN1412, cytokine release syndrome
- MeSH terms
- Adult, Animals, Clinical Trials as Topic, Humans, Leukocytes, Mononuclear, Male, Clinical Trials, Phase I as Topic, Young Adult, Immunomodulation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.